ATAlexandra Tabachnikova

Alexandra Tabachnikova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexandra Tabachnikova has a total of 183 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Associations between salivary HHV-6 and long COVID severity in a cross-sectional, case–control analysis

    by Claire S. Laxton, Alexandra Tabachnikova, Lily Cooke, Kexin Wang, Simone Blaser, Julio Silva, Jamie Wood, Henna S. Nam, Zhenni Lu, Christine Miller, et al.

  • Top Cited Papers

    Dendritic cells control tertiary lymphoid structure development and maintenance in cancer

    by Raphaël Mattiuz, Jesse Boumelha, Emmanouil Aerakis, Jessica Le Berichel, Pauline Hamon, Laszlo Halasz, Abishek Vaidya, Brian Y. Soong, Emir Radkevich, Hye Mi Kim, et al.

    Tertiary lymphoid structures (TLSs) are associated with immunotherapy response, yet the mechanisms controlling their formation and maintenance remain unclear. Using spatial transcriptomics and multiplex imaging across human tumors, we found that CCR7 + mature dendritic cells (DCs) accumulate in TLSs. In a mouse non–small cell lung cancer model that forms mature TLSs, we show that early TLS development requires interferon-γ (IFN-γ)–driven type 1 conventional dendritic cell (cDC1) maturation, migration to tumor-draining lymph nodes (tdLNs), and T cell recruitment. As tumors progress, TLSs persist independently of tdLN T cell egress, coinciding with cDC1 accumulation within intratumoral CCL19 stromal hubs. There, cDC1–major histocompatibility complex class 1 (MHC-I) and –MHC-II concomitant antigen presentation, along with CD40 signaling, sustain TLS, T follicular helper (T FH ) cell pool, germinal centers, and tumor-specific immunoglobulin G (IgG). These findings highlight local mature cDC1s as key TLS orchestrators and potential targets to enhance antitumor TLS function.


  • Open Access

    Early Mucosal Type II Interferon Limits SARS-CoV-2 Replication in Humans

    by Alexander Viloria Winnett, Alexandra Tabachnikova, Jonathan Chen, Kerrie Greene, Anna E Romano, Xinyue Penny Pei, Matthew M Cooper, Julio Silva, Alyssa M Carter, Jialong Jiang, et al.

    COVID-19 vaccines markedly reduce disease severity, but their ability to block infection and transmission remains limited and variable. 1 A better understanding of early mucosal immune programs that constrain viral replication at susceptible upper respiratory sites is needed to develop more effective antiviral strategies. However, temporal and anatomical antiviral dynamics are difficult to resolve without longitudinal, paired-site sampling beginning before infection onset. We quantified longitudinal viral load by RT-qPCR and human gene expression by mRNA sequencing in 1,237 samples prospectively collected daily from the nasal cavity, oral cavity, and oropharynx of 16 individuals starting from the onset of naturally acquired SARS-CoV-2 infection, and 16 age-, sex-, and vaccination-matched uninfected individuals. Here we show that Type I interferon (IFN) responses are initiated concurrently across these upper respiratory sites, even before local viral detection. In contrast, Type II IFN initiation is more spatially variable, and earlier nasal Type II IFN initiation is associated with reduced viral replication, prior COVID-19 vaccination, and higher tissue-resident memory T cell (T RM ) signature expression. These findings demonstrate that in addition to humoral immunity, prior vaccination primes rapid, inducible mucosal Type II IFN responses, likely mediated by rare T RM upon viral encounter, to limit viral replication and spread. ONE SENTENCE SUMMARY: Using a unique study design with temporally-dense, paired sampling of the oral cavity, nasal cavity and oropharynx from the onset of naturally acquired human SARS-CoV-2 infection, we demonstrate that Type I IFN responses are initiated synchronously in the upper respiratory mucosa during early infection, whereas the timing of Type II IFN response initiation is asynchronous but earlier initiation is associated with prior COVID-19 vaccination, enhanced tissue-resident memory T cells signatures, and reduced local viral replication. Graphical : Among participants who prospectively collected daily, paired specimens from multiple upper respiratory anatomical sites while enrolled in a case-ascertained COVID-19 household transmission study conducted in Los Angeles, California between September 2020 and April 2022, a subset of participants were found to initially be negative upon enrollment but later became positive for SARS-CoV-2. These were defined as Cases of naturally acquired, incident SARS-CoV-2 infection, and for whom age, sex, and prior COVID-19 vaccination status matched Control participants without SARS-CoV-2 infection were identified, and demographic data is shown. Samples underwent viral load quantification by RT-qPCR, validated by RT-ddPCR, and human transcriptome sequencing to calculate immune pathway activation and determine the timing of Type I and II IFN response initiation, and expression of a tissue resident memory T cell (T RM ) signature. Differences in the magnitude and timing of these pathways were compared by vaccination status, and by subsequent viral RNA shedding to identify mucosal immune correlates of reduced viral replication. Created in https://BioRender.com .


  • Open Access

    Analysis Of Salivary Herpesviruses Reveals Associations Between HHV-6 And Long COVID Severity

    by Claire S. Laxton, Alexandra Tabachnikova, Lily Cooke, Kexin Wang, Simone Blaser, Julio Silva, Jamie Wood, Henna S. Nam, Zhenni Lu, Christine Miller, et al.

    Background: Reactivation of human herpesviruses (HHVs), particularly EBV, is associated with more severe acute SARS-CoV-2 infections and the development of Long COVID (LC). Observations of higher anti-EBV antibody levels in individuals with LC support the idea that chronic reactivation of HHVs could contribute to LC pathology. HHV shedding in saliva has also been previously associated with saliva hormone levels. This study aims to examine the relationship between salivary shedding of HHV DNA and LC symptoms, as well as cortisol, testosterone, and estradiol levels. Methods: We enrolled 45 participants with LC, and 45 age-sex-matched controls. Surveys and validated health questionnaires were used to collect demographics, medical history, and symptom profiles. Saliva was self-collected at waking, 15, 30, and 45 minutes, and 8 and 16 hours after waking, across two consecutive days. Salivary cortisol, testosterone and estradiol were measured, and extracted nucleic acid was tested for EBV, HSV 1/2, HCMV and HHV-6 A/B using multiplex qPCR, plus SARS-CoV-2 and RNaseP using RT-qPCR. Findings: Detection of salivary EBV and HHV-6 DNA was highest early in the morning. There were no significant differences in salivary cortisol, testosterone, or estradiol, or in EBV or HHV-6 shedding between the LC and control groups. However, salivary HHV-6 DNA levels were positively associated with a greater aggregated LC propensity score, as well as anxiety and depression scores. Interpretation: The observed correlation between salivary HHV-6 shedding and symptom severity suggests HHV-6 may contribute to post-acute disease, though mechanisms remain unclear. While our study did not identify a relationship between salivary EBV shedding and LC, EBV may still play a role at earlier time points in the disease course, or in compartments not sampled here. These findings highlight the potential importance of HHV-6 in LC pathophysiology and underscore the need for longitudinal, multi-compartment studies of herpesvirus reactivation in LC.

  • Open Access

    MARQO pipeline resolves multiparametric cellular and spatial organization in cancer tissue lesions

    by Mark Buckup, Igor Figueiredo, Giorgio Ioannou, Sinem Ozbey, Rafael Cabal, Alexandra Tabachnikova, Leanna Troncoso, Jessica Le Berichel, Zhen Zhao, Stephen C. Ward, et al.

    Multiplex immunostaining analysis remains fragmented, underperforming, and labor-intensive despite tissue proteomic methodologies achieving ever-increasing marker complexity. Here we propose an open-source, semi-supervised automated pipeline that streamlines start-to-finish, single-cell resolution analysis of whole-slide tissue, named Multiplex-imaging Analysis, Registration, Quantification, and Overlaying (MARQO). We compared and validated MARQO using Multiplex Immunohistochemical Consecutive Staining on a Single Slide (MICSSS) using human tumor and adjacent normal tissue samples. Performance was compared with manually-curated pathologist determinations and quantification of multiple markers. We also optimized MARQO to analyze diverse tissue sizes (whole tissue, biopsy, tissue microarray) and staining approaches (singleplex immunohistochemistry, 20-color multiplex immunofluorescence) to determine marker co-expression patterns in multiple human solid cancer types. Lastly, we validated CD8 T cell enrichment in hepatocellular carcinoma responders to neoadjuvant cemiplimab in a phase II clinical trial, further demonstrating MARQO’s ability to provide spatially-resolved in situ mechanisms by providing multiplex whole-slide single-cell resolution data.

  • Open Access

    Supplementary Table from Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors

    by John A. Grout, Philemon Sirven, Andrew M. Leader, Shrisha Maskey, Eglantine Hector, Isabelle Puisieux, Fiona Steffan, Evan Cheng, Navpreet Tung, Mathieu Maurin, et al.

    Supplementary Table from Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors

  • Open Access

    Supplementary Table from Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors

    by John A. Grout, Philemon Sirven, Andrew M. Leader, Shrisha Maskey, Eglantine Hector, Isabelle Puisieux, Fiona Steffan, Evan Cheng, Navpreet Tung, Mathieu Maurin, et al.

    Supplementary Table from Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors

  • Open Access

    Supplementary Table from Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors

    by John A. Grout, Philemon Sirven, Andrew M. Leader, Shrisha Maskey, Eglantine Hector, Isabelle Puisieux, Fiona Steffan, Evan Cheng, Navpreet Tung, Mathieu Maurin, et al.

    Supplementary Table from Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors

  • Open Access

    Supplementary Table from Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors

    by John A. Grout, Philemon Sirven, Andrew M. Leader, Shrisha Maskey, Eglantine Hector, Isabelle Puisieux, Fiona Steffan, Evan Cheng, Navpreet Tung, Mathieu Maurin, et al.

    Supplementary Table from Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors

  • Open Access

    Supplementary Table from Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors

    by John A. Grout, Philemon Sirven, Andrew M. Leader, Shrisha Maskey, Eglantine Hector, Isabelle Puisieux, Fiona Steffan, Evan Cheng, Navpreet Tung, Mathieu Maurin, et al.

    Supplementary Table from Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors